55751
document
Effectiveness and safety of donepezil in boys with fragile x syndrome : a double-blind , randomized , controlled pilot study . The present study was designed as a 12-week , randomized , double-blind , placebo-controlled pilot study to evaluate the effectiveness and safety of donepezil in boys with fragile X syndrome . Twenty boys with fragile X syndrome were randomized to receive 12 weeks of treatment with either placebo or donepezil ( 2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks ) . The outcome measures included change in intelligence quotient scores on Stanford-Binet Intelligence Scale ( Hindi adaptation by Kulshrestha ) , change in behavioral scores by Conners 3 Parent Rating Scale ( Short ) and Childhood Autism Rating Scale , safety , and tolerability of donepezil . The study failed to show significant difference in intelligence quotient and behavioral scales with donepezil therapy over 12 weeks . However , donepezil appeared to be safe and well tolerated .
55752
Intervention_Pharmacological
donepezil
55753
Intervention_Pharmacological
donepezil
55754
Intervention_Pharmacological
placebo
55755
Intervention_Pharmacological
donepezil
55756
Intervention_Pharmacological
donepezil
55757
Intervention_Pharmacological
donepezil
55758
Outcome_Other
effectiveness and safety
55759
Outcome_Mental
change in intelligence quotient scores on Stanford-Binet Intelligence Scale ( Hindi adaptation by Kulshrestha ) , change in behavioral scores by Conners 3 Parent Rating Scale ( Short )
55760
Outcome_Mental
Childhood Autism Rating Scale
55761
Outcome_Other
safety , and tolerability
55762
Outcome_Mental
intelligence quotient
55763
Outcome_Mental
behavioral scales
55764
Participant_Sex
boys
55765
Participant_Condition
fragile x syndrome
55766
Participant_Sex
boys
55767
Participant_Condition
fragile X syndrome .
55768
Participant_Sample-size
Twenty
55769
Participant_Sex
boys
55770
Participant_Condition
fragile X syndrome